Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 598 entries
Sorted by: Best Match Show Resources per page
A study of the longitudinal utilization and switching-patterns of non-steroidal anti-inflammatory drugs using a pharmacy based approach.

Pharmacoepidemiology and drug safety

Sift R, van Staa TP, Abenhaim L, Ebner D.
PMID: 15073777
Pharmacoepidemiol Drug Saf. 1997 Jul;6(4):263-8. doi: 10.1002/(SICI)1099-1557(199707)6:4<263::AID-PDS286>3.0.CO;2-Z.

The extent of the heterogeneity of drug utilization among NSAID users has not been extensively studied. We studied the longitudinal prescribing and switching patterns of NSAID users in a 1-year follow-up study in four German pharmacies. The study population...

Cite
Sift R, van Staa TP, Abenhaim L, et al. A study of the longitudinal utilization and switching-patterns of non-steroidal anti-inflammatory drugs using a pharmacy based approach. Pharmacoepidemiol Drug Saf. 1997;6(4):263-8doi: 10.1002/(SICI)1099-1557(199707)6:4<263::AID-PDS286>3.0.CO;2-Z.
Sift, R., van Staa, T. P., Abenhaim, L., & Ebner, D. (1997). A study of the longitudinal utilization and switching-patterns of non-steroidal anti-inflammatory drugs using a pharmacy based approach. Pharmacoepidemiology and drug safety, 6(4), 263-8. https://doi.org/10.1002/(SICI)1099-1557(199707)6:4<263::AID-PDS286>3.0.CO;2-Z
Sift, R, et al. "A study of the longitudinal utilization and switching-patterns of non-steroidal anti-inflammatory drugs using a pharmacy based approach." Pharmacoepidemiology and drug safety vol. 6,4 (1997): 263-8. doi: https://doi.org/10.1002/(SICI)1099-1557(199707)6:4<263::AID-PDS286>3.0.CO;2-Z
Sift R, van Staa TP, Abenhaim L, Ebner D. A study of the longitudinal utilization and switching-patterns of non-steroidal anti-inflammatory drugs using a pharmacy based approach. Pharmacoepidemiol Drug Saf. 1997 Jul;6(4):263-8. doi: 10.1002/(SICI)1099-1557(199707)6:4<263::AID-PDS286>3.0.CO;2-Z. PMID: 15073777.
Copy Download .nbib Format: NLM
Aminopyrine and blood dyscrasias.

Pharmacoepidemiology and drug safety

Kaufman DW, Issaragrisil S.
PMID: 15073782
Pharmacoepidemiol Drug Saf. 1997 Jul;6(4):292. doi: 10.1002/(SICI)1099-1557(199707)6:4<292::AID-PDS302>3.0.CO;2-F.

No abstract available.

Cite
Kaufman DW, Issaragrisil S. Aminopyrine and blood dyscrasias. Pharmacoepidemiol Drug Saf. 1997;6(4):292doi: 10.1002/(SICI)1099-1557(199707)6:4<292::AID-PDS302>3.0.CO;2-F.
Kaufman, D. W., & Issaragrisil, S. (1997). Aminopyrine and blood dyscrasias. Pharmacoepidemiology and drug safety, 6(4), 292. https://doi.org/10.1002/(SICI)1099-1557(199707)6:4<292::AID-PDS302>3.0.CO;2-F
Kaufman, D W, and Issaragrisil, S. "Aminopyrine and blood dyscrasias." Pharmacoepidemiology and drug safety vol. 6,4 (1997): 292. doi: https://doi.org/10.1002/(SICI)1099-1557(199707)6:4<292::AID-PDS302>3.0.CO;2-F
Kaufman DW, Issaragrisil S. Aminopyrine and blood dyscrasias. Pharmacoepidemiol Drug Saf. 1997 Jul;6(4):292. doi: 10.1002/(SICI)1099-1557(199707)6:4<292::AID-PDS302>3.0.CO;2-F. PMID: 15073782.
Copy Download .nbib Format: NLM
Erythromycin prolongs the QTc interval among patients with pneumonia.

Pharmacoepidemiology and drug safety

Freeman J, Platt R.
PMID: 15073800
Pharmacoepidemiol Drug Saf. 1997 Jan;6(1):13-9. doi: 10.1002/(SICI)1099-1557(199701)6:1<13::AID-PDS251>3.0.CO;2-0.

Erythromycin is commonly used to treat simple community-acquired pneumonia. We measured the prolongation in QT(c) intervals in EKGs associated with intravenous erythromycin administration among patients hospitalized for simple pneumonia (DRGs 89 and 90). We reviewed the medical records of...

Cite
Freeman J, Platt R. Erythromycin prolongs the QTc interval among patients with pneumonia. Pharmacoepidemiol Drug Saf. 1997;6(1):13-9doi: 10.1002/(SICI)1099-1557(199701)6:1<13::AID-PDS251>3.0.CO;2-0.
Freeman, J., & Platt, R. (1997). Erythromycin prolongs the QTc interval among patients with pneumonia. Pharmacoepidemiology and drug safety, 6(1), 13-9. https://doi.org/10.1002/(SICI)1099-1557(199701)6:1<13::AID-PDS251>3.0.CO;2-0
Freeman, J, and Platt, R. "Erythromycin prolongs the QTc interval among patients with pneumonia." Pharmacoepidemiology and drug safety vol. 6,1 (1997): 13-9. doi: https://doi.org/10.1002/(SICI)1099-1557(199701)6:1<13::AID-PDS251>3.0.CO;2-0
Freeman J, Platt R. Erythromycin prolongs the QTc interval among patients with pneumonia. Pharmacoepidemiol Drug Saf. 1997 Jan;6(1):13-9. doi: 10.1002/(SICI)1099-1557(199701)6:1<13::AID-PDS251>3.0.CO;2-0. PMID: 15073800.
Copy Download .nbib Format: NLM
A prospective study of falls after benzodiazepine use: a comparison of new and repeat use.

Pharmacoepidemiology and drug safety

Maxwell CJ, Neutel CI, Hirdes JP.
PMID: 15073802
Pharmacoepidemiol Drug Saf. 1997 Jan;6(1):27-35. doi: 10.1002/(SICI)1099-1557(199701)6:1<27::AID-PDS240>3.0.CO;2-S.

Although research has consistently demonstrated an increased risk for falls and fall-related fractures among persons receiving benzodiazepine (BZD) medications, the association between new as compared with chronic use and fall-related morbidity among different age groups is less clear. The...

Cite
Maxwell CJ, Neutel CI, Hirdes JP. A prospective study of falls after benzodiazepine use: a comparison of new and repeat use. Pharmacoepidemiol Drug Saf. 1997;6(1):27-35doi: 10.1002/(SICI)1099-1557(199701)6:1<27::AID-PDS240>3.0.CO;2-S.
Maxwell, C. J., Neutel, C. I., & Hirdes, J. P. (1997). A prospective study of falls after benzodiazepine use: a comparison of new and repeat use. Pharmacoepidemiology and drug safety, 6(1), 27-35. https://doi.org/10.1002/(SICI)1099-1557(199701)6:1<27::AID-PDS240>3.0.CO;2-S
Maxwell, C J, et al. "A prospective study of falls after benzodiazepine use: a comparison of new and repeat use." Pharmacoepidemiology and drug safety vol. 6,1 (1997): 27-35. doi: https://doi.org/10.1002/(SICI)1099-1557(199701)6:1<27::AID-PDS240>3.0.CO;2-S
Maxwell CJ, Neutel CI, Hirdes JP. A prospective study of falls after benzodiazepine use: a comparison of new and repeat use. Pharmacoepidemiol Drug Saf. 1997 Jan;6(1):27-35. doi: 10.1002/(SICI)1099-1557(199701)6:1<27::AID-PDS240>3.0.CO;2-S. PMID: 15073802.
Copy Download .nbib Format: NLM
Establishing rapid response capability: a German approach.

Pharmacoepidemiology and drug safety

Lewis MA.
PMID: 15073803
Pharmacoepidemiol Drug Saf. 1997 Jan;6(1):37-40. doi: 10.1002/(SICI)1099-1557(199701)6:1<37::AID-PDS239>3.0.CO;2-1.

No abstract available.

Cite
Lewis MA. Establishing rapid response capability: a German approach. Pharmacoepidemiol Drug Saf. 1997;6(1):37-40doi: 10.1002/(SICI)1099-1557(199701)6:1<37::AID-PDS239>3.0.CO;2-1.
Lewis, M. A. (1997). Establishing rapid response capability: a German approach. Pharmacoepidemiology and drug safety, 6(1), 37-40. https://doi.org/10.1002/(SICI)1099-1557(199701)6:1<37::AID-PDS239>3.0.CO;2-1
Lewis, M A. "Establishing rapid response capability: a German approach." Pharmacoepidemiology and drug safety vol. 6,1 (1997): 37-40. doi: https://doi.org/10.1002/(SICI)1099-1557(199701)6:1<37::AID-PDS239>3.0.CO;2-1
Lewis MA. Establishing rapid response capability: a German approach. Pharmacoepidemiol Drug Saf. 1997 Jan;6(1):37-40. doi: 10.1002/(SICI)1099-1557(199701)6:1<37::AID-PDS239>3.0.CO;2-1. PMID: 15073803.
Copy Download .nbib Format: NLM
US adverse drug reaction surveillance 1989-1994.

Pharmacoepidemiology and drug safety

Faich GA.
PMID: 15073810
Pharmacoepidemiol Drug Saf. 1996 Nov;5(6):393-8. doi: 10.1002/(SICI)1099-1557(199611)5:6<393::AID-PDS235>3.0.CO;2-H.

Adverse drug reaction surveillance conducted by the US Federal Food and Drug Administration (FDA) is important for detecting new safety information about pharmaceuticals. FDA has sought to stimulate reporting of reactions by practitioners and manufacturers. Over the five years...

Cite
Faich GA. US adverse drug reaction surveillance 1989-1994. Pharmacoepidemiol Drug Saf. 1996;5(6):393-8doi: 10.1002/(SICI)1099-1557(199611)5:6<393::AID-PDS235>3.0.CO;2-H.
Faich, G. A. (1996). US adverse drug reaction surveillance 1989-1994. Pharmacoepidemiology and drug safety, 5(6), 393-8. https://doi.org/10.1002/(SICI)1099-1557(199611)5:6<393::AID-PDS235>3.0.CO;2-H
Faich, G A. "US adverse drug reaction surveillance 1989-1994." Pharmacoepidemiology and drug safety vol. 5,6 (1996): 393-8. doi: https://doi.org/10.1002/(SICI)1099-1557(199611)5:6<393::AID-PDS235>3.0.CO;2-H
Faich GA. US adverse drug reaction surveillance 1989-1994. Pharmacoepidemiol Drug Saf. 1996 Nov;5(6):393-8. doi: 10.1002/(SICI)1099-1557(199611)5:6<393::AID-PDS235>3.0.CO;2-H. PMID: 15073810.
Copy Download .nbib Format: NLM
Incidence of pelvic inflammatory disease among women treated for gonorrhea or chlamydia.

Pharmacoepidemiology and drug safety

Rothman KJ, Lanza L, Lal A, Peskin EG, Dreyer NA.
PMID: 15073812
Pharmacoepidemiol Drug Saf. 1996 Nov;5(6):409-14. doi: 10.1002/(SICI)1099-1557(199611)5:6<409::AID-PDS232>3.0.CO;2-E.

BACKGROUND: No estimate exists of the incidence of pelvic inflammatory disease (PID) after the occurrence of a recent bout of sexually transmitted disease (STD).METHODS: We used a computerized data file of prescriptions and medical encounters from the Fallon Community...

Cite
Rothman KJ, Lanza L, Lal A, et al. Incidence of pelvic inflammatory disease among women treated for gonorrhea or chlamydia. Pharmacoepidemiol Drug Saf. 1996;5(6):409-14doi: 10.1002/(SICI)1099-1557(199611)5:6<409::AID-PDS232>3.0.CO;2-E.
Rothman, K. J., Lanza, L., Lal, A., Peskin, E. G., & Dreyer, N. A. (1996). Incidence of pelvic inflammatory disease among women treated for gonorrhea or chlamydia. Pharmacoepidemiology and drug safety, 5(6), 409-14. https://doi.org/10.1002/(SICI)1099-1557(199611)5:6<409::AID-PDS232>3.0.CO;2-E
Rothman, K J, et al. "Incidence of pelvic inflammatory disease among women treated for gonorrhea or chlamydia." Pharmacoepidemiology and drug safety vol. 5,6 (1996): 409-14. doi: https://doi.org/10.1002/(SICI)1099-1557(199611)5:6<409::AID-PDS232>3.0.CO;2-E
Rothman KJ, Lanza L, Lal A, Peskin EG, Dreyer NA. Incidence of pelvic inflammatory disease among women treated for gonorrhea or chlamydia. Pharmacoepidemiol Drug Saf. 1996 Nov;5(6):409-14. doi: 10.1002/(SICI)1099-1557(199611)5:6<409::AID-PDS232>3.0.CO;2-E. PMID: 15073812.
Copy Download .nbib Format: NLM
Large scale safety study of ketoprofen 25 mg (Toprec) in febrile and painful conditions.

Pharmacoepidemiology and drug safety

Moore N, Vuillemin N, Abiteboul M, Boudignat O, Paliwoda A, Robin JL, Jacobs LD.
PMID: 15073815
Pharmacoepidemiol Drug Saf. 1996 Sep;5(5):295-302. doi: 10.1002/(SICI)1099-1557(199609)5:5<295::AID-PDS233>3.0.CO;2-0.

OBJECTIVE: To assess the safety, tolerability and efficacy of low-dose ketoprofen (75-150 mg daily for 5 to 15 days) in a general practice setting.DESIGN: Open label, non-controlled study of ketoprofen 25 mg tablets in the treatment of pain in...

Cite
Moore N, Vuillemin N, Abiteboul M, et al. Large scale safety study of ketoprofen 25 mg (Toprec) in febrile and painful conditions. Pharmacoepidemiol Drug Saf. 1996;5(5):295-302doi: 10.1002/(SICI)1099-1557(199609)5:5<295::AID-PDS233>3.0.CO;2-0.
Moore, N., Vuillemin, N., Abiteboul, M., Boudignat, O., Paliwoda, A., Robin, J. L., & Jacobs, L. D. (1996). Large scale safety study of ketoprofen 25 mg (Toprec) in febrile and painful conditions. Pharmacoepidemiology and drug safety, 5(5), 295-302. https://doi.org/10.1002/(SICI)1099-1557(199609)5:5<295::AID-PDS233>3.0.CO;2-0
Moore, N, et al. "Large scale safety study of ketoprofen 25 mg (Toprec) in febrile and painful conditions." Pharmacoepidemiology and drug safety vol. 5,5 (1996): 295-302. doi: https://doi.org/10.1002/(SICI)1099-1557(199609)5:5<295::AID-PDS233>3.0.CO;2-0
Moore N, Vuillemin N, Abiteboul M, Boudignat O, Paliwoda A, Robin JL, Jacobs LD. Large scale safety study of ketoprofen 25 mg (Toprec) in febrile and painful conditions. Pharmacoepidemiol Drug Saf. 1996 Sep;5(5):295-302. doi: 10.1002/(SICI)1099-1557(199609)5:5<295::AID-PDS233>3.0.CO;2-0. PMID: 15073815.
Copy Download .nbib Format: NLM
Usage and users of natural remedies in a middle-aged population: demographic and psychosocial characteristics. Results from the Malmö Diet and Cancer Study.

Pharmacoepidemiology and drug safety

Wallström P, Elmståhl S, Johansson U, Ostergren PO, Hanson BS.
PMID: 15073816
Pharmacoepidemiol Drug Saf. 1996 Sep;5(5):303-14. doi: 10.1002/(SICI)1099-1557(199609)5:5<303::AID-PDS227>3.0.CO;2-1.

BACKGROUND: In Sweden, large amounts of money are spent annually on natural remedies (NRs), in spite of the fact that most products in this category lack scientific documentation of their efficacy and side-effects. The usage and users of natural...

Cite
Wallström P, Elmståhl S, Johansson U, et al. Usage and users of natural remedies in a middle-aged population: demographic and psychosocial characteristics. Results from the Malmö Diet and Cancer Study. Pharmacoepidemiol Drug Saf. 1996;5(5):303-14doi: 10.1002/(SICI)1099-1557(199609)5:5<303::AID-PDS227>3.0.CO;2-1.
Wallström, P., Elmståhl, S., Johansson, U., Ostergren, P. O., & Hanson, B. S. (1996). Usage and users of natural remedies in a middle-aged population: demographic and psychosocial characteristics. Results from the Malmö Diet and Cancer Study. Pharmacoepidemiology and drug safety, 5(5), 303-14. https://doi.org/10.1002/(SICI)1099-1557(199609)5:5<303::AID-PDS227>3.0.CO;2-1
Wallström, P, et al. "Usage and users of natural remedies in a middle-aged population: demographic and psychosocial characteristics. Results from the Malmö Diet and Cancer Study." Pharmacoepidemiology and drug safety vol. 5,5 (1996): 303-14. doi: https://doi.org/10.1002/(SICI)1099-1557(199609)5:5<303::AID-PDS227>3.0.CO;2-1
Wallström P, Elmståhl S, Johansson U, Ostergren PO, Hanson BS. Usage and users of natural remedies in a middle-aged population: demographic and psychosocial characteristics. Results from the Malmö Diet and Cancer Study. Pharmacoepidemiol Drug Saf. 1996 Sep;5(5):303-14. doi: 10.1002/(SICI)1099-1557(199609)5:5<303::AID-PDS227>3.0.CO;2-1. PMID: 15073816.
Copy Download .nbib Format: NLM
The use of confidential medical data and postmarketing surveillance: a survey of the opinion of patients.

Pharmacoepidemiology and drug safety

de Wit ME, Porsius AJ, Stricker BH.
PMID: 15073818
Pharmacoepidemiol Drug Saf. 1996 Sep;5(5):321-4. doi: 10.1002/(SICI)1099-1557(199609)5:5<321::AID-PDS231>3.0.CO;2-M.

OBJECTIVES: To study the perceptions of patients regarding privacy in relation to the performance of postmarketing surveillance studies.DESIGN: A population-based cross-sectional study (survey).SETTING: Out of a source population of 1030 pharmacists a random sample of 30 (2.9%) was taken....

Cite
de Wit ME, Porsius AJ, Stricker BH. The use of confidential medical data and postmarketing surveillance: a survey of the opinion of patients. Pharmacoepidemiol Drug Saf. 1996;5(5):321-4doi: 10.1002/(SICI)1099-1557(199609)5:5<321::AID-PDS231>3.0.CO;2-M.
de Wit, M. E., Porsius, A. J., & Stricker, B. H. (1996). The use of confidential medical data and postmarketing surveillance: a survey of the opinion of patients. Pharmacoepidemiology and drug safety, 5(5), 321-4. https://doi.org/10.1002/(SICI)1099-1557(199609)5:5<321::AID-PDS231>3.0.CO;2-M
de Wit, M E, et al. "The use of confidential medical data and postmarketing surveillance: a survey of the opinion of patients." Pharmacoepidemiology and drug safety vol. 5,5 (1996): 321-4. doi: https://doi.org/10.1002/(SICI)1099-1557(199609)5:5<321::AID-PDS231>3.0.CO;2-M
de Wit ME, Porsius AJ, Stricker BH. The use of confidential medical data and postmarketing surveillance: a survey of the opinion of patients. Pharmacoepidemiol Drug Saf. 1996 Sep;5(5):321-4. doi: 10.1002/(SICI)1099-1557(199609)5:5<321::AID-PDS231>3.0.CO;2-M. PMID: 15073818.
Copy Download .nbib Format: NLM
Cohort maintenance and comparability in a pharmacoepidemiologic study using a commercial consumer panel to recruit comparators.

Pharmacoepidemiology and drug safety

Gardner JS, Szpunar CA, O'Connell MJ, Facklam DP, Mariano JP, Borden EK, Leinweber FB.
PMID: 15073822
Pharmacoepidemiol Drug Saf. 1996 Jul;5(4):207-14. doi: 10.1002/(SICI)1099-1557(199607)5:4<207::AID-PDS190>3.0.CO;2-I.

The Upjohn Consumer Health Survey (UCHS) was a prospective, observational study of users of ROGAINE (REGAINE in international markets) Topical Solution 2% (N=11,122) and a Comparator cohort (N=11,173) which was selected and group matched by stratified random sampling from...

Cite
Gardner JS, Szpunar CA, O'Connell MJ, et al. Cohort maintenance and comparability in a pharmacoepidemiologic study using a commercial consumer panel to recruit comparators. Pharmacoepidemiol Drug Saf. 1996;5(4):207-14doi: 10.1002/(SICI)1099-1557(199607)5:4<207::AID-PDS190>3.0.CO;2-I.
Gardner, J. S., Szpunar, C. A., O'Connell, M. J., Facklam, D. P., Mariano, J. P., Borden, E. K., & Leinweber, F. B. (1996). Cohort maintenance and comparability in a pharmacoepidemiologic study using a commercial consumer panel to recruit comparators. Pharmacoepidemiology and drug safety, 5(4), 207-14. https://doi.org/10.1002/(SICI)1099-1557(199607)5:4<207::AID-PDS190>3.0.CO;2-I
Gardner, J S, et al. "Cohort maintenance and comparability in a pharmacoepidemiologic study using a commercial consumer panel to recruit comparators." Pharmacoepidemiology and drug safety vol. 5,4 (1996): 207-14. doi: https://doi.org/10.1002/(SICI)1099-1557(199607)5:4<207::AID-PDS190>3.0.CO;2-I
Gardner JS, Szpunar CA, O'Connell MJ, Facklam DP, Mariano JP, Borden EK, Leinweber FB. Cohort maintenance and comparability in a pharmacoepidemiologic study using a commercial consumer panel to recruit comparators. Pharmacoepidemiol Drug Saf. 1996 Jul;5(4):207-14. doi: 10.1002/(SICI)1099-1557(199607)5:4<207::AID-PDS190>3.0.CO;2-I. PMID: 15073822.
Copy Download .nbib Format: NLM
Are the adverse drug reactions of amoxycillin and amoxycillin-clavulanic acid similar?.

Pharmacoepidemiology and drug safety

Martinez-Mir I, Ferrer JM, Palop V, Estan L, Rubio E, Morales-Olivas FJ.
PMID: 15073827
Pharmacoepidemiol Drug Saf. 1996 Jul;5(4):247-54. doi: 10.1002/(SICI)1099-1557(199607)5:4<247::AID-PDS220>3.0.CO;2-I.

UNLABELLED: In an attempt to assess the relative toxicity of amoxycillin and amoxycillin-clavulanic acid, we compared the adverse drug reactions reports collected using the spontaneous reporting system of a Regional Drug Surveillance Centre of Spain for both drugs between...

Cite
Martinez-Mir I, Ferrer JM, Palop V, et al. Are the adverse drug reactions of amoxycillin and amoxycillin-clavulanic acid similar?. Pharmacoepidemiol Drug Saf. 1996;5(4):247-54doi: 10.1002/(SICI)1099-1557(199607)5:4<247::AID-PDS220>3.0.CO;2-I.
Martinez-Mir, I., Ferrer, J. M., Palop, V., Estan, L., Rubio, E., & Morales-Olivas, F. J. (1996). Are the adverse drug reactions of amoxycillin and amoxycillin-clavulanic acid similar?. Pharmacoepidemiology and drug safety, 5(4), 247-54. https://doi.org/10.1002/(SICI)1099-1557(199607)5:4<247::AID-PDS220>3.0.CO;2-I
Martinez-Mir, I, et al. "Are the adverse drug reactions of amoxycillin and amoxycillin-clavulanic acid similar?." Pharmacoepidemiology and drug safety vol. 5,4 (1996): 247-54. doi: https://doi.org/10.1002/(SICI)1099-1557(199607)5:4<247::AID-PDS220>3.0.CO;2-I
Martinez-Mir I, Ferrer JM, Palop V, Estan L, Rubio E, Morales-Olivas FJ. Are the adverse drug reactions of amoxycillin and amoxycillin-clavulanic acid similar?. Pharmacoepidemiol Drug Saf. 1996 Jul;5(4):247-54. doi: 10.1002/(SICI)1099-1557(199607)5:4<247::AID-PDS220>3.0.CO;2-I. PMID: 15073827.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 598 entries